Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322744 | 0.89 | PIK3CA (0.46) | MAPTPKMMEN1KMT2ALMNA | |
| SCHEMBL20832864 | 0.86 | PIK3CA (0.38) | MAPTPOLBPKMMEN1KMT2A | |
| SCHEMBL18181295 | 0.85 | IRAK1 (0.40) | MAPTPOLBPKMMEN1KMT2A | |
| SCHEMBL11233906 | 0.81 | MMP12 (0.45) | MAPTPOLBPKMMEN1KMT2A | |
| SCHEMBL18172300 | 0.80 | MAPT (0.36) | MAPTMEN1KMT2ACYP2C19RAB9A | |
| SCHEMBL18172301 | 0.79 | PIM1 (0.44) | MEN1KMT2ALMNACYP2C19ALDH1A1 | |
| SCHEMBL4039191 | 0.79 | MAPT (0.66) | MAPTPOLBPKMMEN1KMT2A | |
| SCHEMBL6527214 | 0.79 | MAPT (0.58) | MAPTPOLBPKMMEN1KMT2A | |
| SCHEMBL18181083 | 0.78 | CYP1A2 (0.58) | MAPTPOLBPKMLMNACYP2C19 | |
| SCHEMBL3997225 | 0.77 | PRKCQ (0.44) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107750251-B | Isoxazolyl-substituted imidazopyridines | 塞尔森瑞科有限责任公司 | 2020-09-01 | — | — | CN | disclosed |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | CELLCENTRIC LTD (GB) | 2019-10-01 | — | — | US | disclosed |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | CELLCENTRIC LTD (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3286188-B1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3286188-B1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2018-04-19 | — | — | US | disclosed |
| EP-3286188-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | Cellcentric Ltd (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016170323-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016170323-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | CELLCENTRIC LTD (GB) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105519-A1 | ISOXAZOLYL SUBSTITUTED IMIDAZOPYRIDINES | EP300, HDAC3, HDAC1 | MAPT 4493/4885POLB 2112/4885PKM 3009/4885 |
| US-10428065-B2 | Isoxazolyl substituted imidazopyridines | EP300, HDAC3, HDAC1 | MAPT 4493/4885POLB 2112/4885PKM 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.